ReviewWorld journal of clinical cases2017
Primary prevention of cardiovascular disease in older adults in China.
Review in World journal of clinical cases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Premature mortality projection for cardiovascular diseases to 2030: a sub-national evaluation towards the SDG 3.4 goals in China.The Lancet regional health. Western Pacific · 2026Article
- Association between residential proximity to major roadways and nonfatal cardiovascular disease in Chinese older adults: a nationwide study.Scientific reports · 2025Article
- Reference intervals for coagulation parameters in chinese adults stratified by sex and age.Scientific reports · 2025Article
- Willingness to use remote patient monitoring among cardiovascular patients in a resource-limited setting: a cross-sectional study.Frontiers in digital health · 2024Article
- Long-term care status for the elderly with different levels of physical ability: a cross-sectional survey in first-tier cities of China.BMC health services research · 2023Article
- Article
- Age-standardized mortality, disability-adjusted life-years and healthy life expectancy in different cultural regions of Guangdong, China: a population-based study of 2005-2015.BMC public health · 2020Article
- Exercise for Prevention and Relief of Cardiovascular Disease: Prognoses, Mechanisms, and Approaches.Oxidative medicine and cellular longevity · 2019Review
- Non-communicable Diseases and Cognitive Impairment: Pathways and Shared Behavioral Risk Factors Among Older Chinese.Frontiers in public health · 2019Review
- Baicalin Protects against Thrombin-Induced Cell Injury in Human Umbilical Vein Endothelial Cells.BioMed research international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past two decades, the percentage of Chinese who is 60 years or older has increased from 5.2% in 1995 to 10.5% in 2015. Approximately 16% of the population in China was 60 years old and above in 2015. Since 1990, cardiovascular disease (CVD) has been the leading cause of death in China. Cardiovascular medications of older adults are usually more complicated than younger age groups due to polypharmacy, the presence of comorbidities and more susceptible to treatment-related adverse outcomes. Therefore, effective primary prevention of CVD for older adults is important in sustaining the health of older adults and reducing the burden of the healthcare system. Proper management of CVD-related risk factors, such as hypertension, dyslipidemia, diabetes and obesity, can remarkably reduce risks of CVDs in older Chinese. These risk factors can be modified by managing blood pressure, glucose and lipids
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.